ALKS Q2 2019 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$280M-8.1% YoY

Gross Profit

$234M83.5% margin

Operating Income

-$36M-12.8% margin

Net Income

-$42M-15.0% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+25.4%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$39M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$661M

Stockholders' Equity

$1.1B

Cash & Equivalents

$196M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$280M	$305M	-8.1%
Gross Profit	$234M	$261M	-10.6%
Operating Income	-$36M	-$102,000	-35118.6%
Net Income	-$42M	-$33M	-28.6%

Revenue Segments

Product

$137M49%

Manufactured Product And Royalty

$128M46%

Research And Development

$14M5%

License

$1M0%